In Vitro & In Vivo Diagnostic Substances
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BlackRock, Inc. | 33.43M | $300.0M | 15.31% | +810.0K | 2026-06-30 |
| Neuberger Berman Group LLC | 16.57M | $148.0M | 7.59% | +8.82M | 2026-06-30 |
| Vanguard Portfolio Management LLC | 13.04M | $117.0M | 5.97% | +206.5K | 2026-06-30 |
| Dimensional Fund Advisors LP | 9.83M | $88.0M | 4.50% | +696.2K | 2026-06-30 |
| Vanguard Capital Management LLC | 9.66M | $86.0M | 4.42% | +90.2K | 2026-06-30 |
| SG Americas Securities, LLC | 9.35M | $84.0M | 4.28% | +3.09M | 2026-06-30 |
| T. Rowe Price Investment Management, Inc. | 9.33M | $83.0M | 4.28% | -829.5K | 2026-06-30 |
| State Street Corp | 8.95M | $80.0M | 4.10% | +356.0K | 2026-06-30 |
| Gates Capital Management, Inc. | 8.74M | $78.0M | 4.00% | +2.48M | 2026-06-30 |
| Hudson Bay Capital Management LP | 6.50M | $58.0M | 2.98% | -180 | 2026-06-30 |
